NASHVILLE, Tenn., Oct. 31,
2024 /PRNewswire/ -- Cumberland Pharmaceuticals
Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced
today that it will release its third quarter 2024 financial results
and provide a company update after the market closes on
Thursday, Nov. 7, 2024.
A conference call will be held on Nov.
7 at 4:30 p.m. Eastern Time to
discuss the results. To participate in the call, please register at
https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384.
Once registered, participants can dial in from their phone using
a dial-in and PIN number that will be provided to them.
Alternatively, they can choose a "Call Me" option to have the
system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be
accessed via Cumberland's website
or by visiting https://edge.media-server.com/mmc/p/cm7m7ea3.
Cumberland Pharmaceuticals is a specialty pharmaceutical company
focused on providing unique products that improve patient care. The
company develops, acquires, and commercializes products for the
hospital acute care, gastroenterology and oncology market
segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine)
injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection,
for the treatment of pain and fever;
- Kristalose® (lactulose) for oral
solution, a prescription laxative, for the treatment of
constipation;
- Sancuso® (granisetron)
transdermal system, for the prevention of nausea and vomiting in
patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection,
to raise serum sodium levels in hospitalized patients with
euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection,
for the treatment of certain serious bacterial infections
including
hospital-acquired and ventilator-associated bacterial pneumonia, as
well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs
underway evaluating its ifetroban product candidate in patients
with Systemic Sclerosis, cardiomyopathy associated with Duchenne
Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.
For more information on Cumberland's approved products, including full
prescribing information, please visit links to the individual
product websites, which can be found on the company's website at
www.cumberlandpharma.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-third-quarter-2024-financial-results-302293344.html
SOURCE Cumberland Pharmaceuticals Inc.
